Exploring the Roles of m6A-Modified circRNAs in Myasthenia Gravis Based on Multi-Omics Analysis

Shuang Li1, Yu Zhang2, Geyu Liu1,3

  • 1Department of Neurology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.

PubMed

Insights

This study investigates m6A-modified circRNAs in myasthenia gravis (MG), an autoimmune disease. Researchers identified four candidate circRNAs, with two showing downregulated m6A methylation in MG patients, suggesting potential biomarkers and therapeutic targets.

Area of Science:

  • Immunology
  • Epigenetics
  • Molecular Biology

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder driven by autoantibodies.
  • The role of m6A-modified circRNAs in MG pathogenesis is not well understood.
  • m6A-modified circRNAs are implicated in other autoimmune diseases.

Purpose of the Study:

  • To explore the role of m6A-modified circRNAs in the pathogenesis of myasthenia gravis.
  • To identify potential epigenetic biomarkers and therapeutic targets for MG.

Main Methods:

  • Peripheral blood mononuclear cells from MG patients and healthy controls were analyzed using m6A-circRNA epitranscriptomic microarray and RNA sequencing.
  • Differential expression analysis and network construction were performed.
  • A random walk with restart algorithm was used to identify candidate circRNAs, validated by MeRIP-qPCR.

Main Results:

  • Four candidate m6A-modified circRNAs (hsa_circ_0084735, hsa_circ_0018652, hsa_circ_0025731, hsa_circ_0030997) were identified.
  • hsa_circ_0084735 and hsa_circ_0025731 showed downregulated m6A methylation levels in MG patients.
  • Candidate circRNAs exhibited varying correlations with different immune cell populations.

Conclusions:

  • This study provides the first exploration of MG pathogenesis at the epigenetic transcriptome level.
  • Identified circRNAs may serve as novel biomarkers and therapeutic targets for myasthenia gravis.
  • Findings open new avenues for MG research and treatment strategies.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
744
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
4.9K